专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20160287695A1 COMPOSITIONS AND METHODS FOR GLIOBLASTOMA TREATMENT 审中-公开
标题翻译： GLIOBLASTOMA治疗的组合物和方法
公开(公告)号：US20160287695A1
公开(公告)日：2016-10-06
申请号：US15155983
申请日：2016-05-16
申请人： CHILDREN'S HOSPITAL OF EASTERN ONTARIO RESEARCH INSTITUTE INC.
发明人： David F. STOJDL
IPC分类号： A61K39/205 , C12N7/00
摘要： The present disclosure concerns an oncolytic virus for the treatment of cancer, such as in brain cancer, for example glioblastoma. The oncolytic virus may exhibit reduced levels of neurotoxicity. The oncolytic virus may be an isolated viral particle capable of producing a cDNA polynucleotide that includes a sequence according to SEQ ID NO: 1 when the virus is in a host cell. The oncolytic virus may be an isolated viral particle that includes an RNA polynuclotide that includes a sequence according to SEQ ID NO: 2. The oncolytic virus may be an isolated viral particle having a genome that includes open reading frames that encode: proteins having sequences comprising SEQ ID NOs: 3, 4, 5, 6 and 7; or variants thereof.
摘要翻译：本公开涉及用于治疗癌症的溶瘤病毒，例如在脑癌中，例如成胶质细胞瘤。溶瘤病毒可能表现出降低的神经毒性水平。当病毒在宿主细胞中时，溶瘤病毒可以是能够产生包含根据SEQ ID NO：1的序列的cDNA多核苷酸的分离的病毒颗粒。溶瘤病毒可以是分离的病毒颗粒，其包括包含根据SEQ ID NO：2的序列的RNA多核苷酸。溶瘤病毒可以是分离的病毒颗粒，其具有包含开放阅读框的基因组，所述基因组编码：具有包含 SEQ ID NO：3,4,5,6和7; 或其变体。

2. 发明公开

US20230293668A1 COMPOSITIONS AND METHODS FOR GLIOBLASTOMA TREATMENT 审中-公开
公开(公告)号：US20230293668A1
公开(公告)日：2023-09-21
申请号：US18300124
申请日：2023-04-13
申请人： CHILDREN'S HOSPITAL OF EASTERN ONTARIO RESEARCH INSTITUTE INC.
发明人： David F. STOJDL
IPC分类号： A61K39/205 , A61K35/766 , C07K14/005 , C12N7/00
CPC分类号： A61K39/205 , A61K35/766 , C07K14/005 , C12N7/00 , C12N2760/20021 , C12N2760/20022 , C12N2760/20032 , A61K38/00
摘要： The present disclosure concerns an oncolytic virus for the treatment of cancer, such as in brain cancer, for example glioblastoma. The oncolytic virus may exhibit reduced levels of neurotoxicity. The oncolytic virus may be an isolated viral particle capable of producing a cDNA polynucleotide that includes a sequence according to SEQ ID NO: 1 when the virus is in a host cell. The oncolytic virus may be an isolated viral particle that includes an RNA polynucleotide that includes a sequence according to SEQ ID NO: 2. The oncolytic virus may be an isolated viral particle having a genome that includes open reading frames that encode: proteins having sequences comprising SEQ ID NOs: 3, 4, 5, 6 and 7; or variants thereof.

3. 发明申请

US20140037584A1 ONCOLYTIC RHABDOVIRUS 审中-公开
公开(公告)号：US20140037584A1
公开(公告)日：2014-02-06
申请号：US13919787
申请日：2013-06-17
申请人： Children's Hospital of Eastern Ontario Research Institute Inc.
发明人： David F. STOJDL
IPC分类号： A61K45/06 , A61K35/76
CPC分类号： A61K35/766 , A61K35/761 , A61K35/763 , A61K35/768 , A61K45/06 , C12N7/00 , C12N2760/20032 , C12N2760/20045 , C12N2760/20221 , C12N2760/20222 , C12N2760/20232 , C12N2760/20271 , C12N2810/6081
摘要： Embodiments of the invention include compositions and methods related to non-VSV rhabdoviruses and their use as anti-cancer therapeutics. Such rhabdoviruses possess tumor cell killing properties in vitro and in vivo.

4. 发明申请

US20210023201A1 COMPOSITIONS AND METHODS FOR GLIOBLASTOMA TREATMENT 有权
公开(公告)号：US20210023201A1
公开(公告)日：2021-01-28
申请号：US17020490
申请日：2020-09-14
申请人： CHILDREN'S HOSPITAL OF EASTERN ONTARIO RESEARCH INSTITUTE INC.
发明人： David F. STOJDL
IPC分类号： A61K39/205 , A61K35/766 , C07K14/005 , C12N7/00
摘要： The present disclosure concerns an oncolytic virus for the treatment of cancer, such as in brain cancer, for example glioblastoma. The oncolytic virus may exhibit reduced levels of neurotoxicity. The oncolytic virus may be an isolated viral particle capable of producing a cDNA polynucleotide that includes a sequence according to SEQ ID NO: 1 when the virus is in a host cell. The oncolytic virus may be an isolated viral particle that includes an RNA polynuclotide that includes a sequence according to SEQ ID NO: 2. The oncolytic virus may be an isolated viral particle having a genome that includes open reading frames that encode: proteins having sequences comprising SEQ ID NOs: 3, 4, 5, 6 and 7; or variants thereof.

5. 发明申请

US20160106820A1 VACCINE COMPOSITION 审中-公开
标题翻译：疫苗组合物
公开(公告)号：US20160106820A1
公开(公告)日：2016-04-21
申请号：US14769035
申请日：2014-02-20
申请人： CHILDREN'S HOSPITAL OF EASTERN ONTARIO RESEARCH INSTITUTE INC. , OTTAWA HOSPITAL RESEARCH INSTITUTE , MCMASTER UNIVERSITY
发明人： David F. STOJDL , John Cameron BELL , Brian LICHTY , Jonathan POL
IPC分类号： A61K39/00 , A61K39/12 , C12N7/00
CPC分类号： A61K39/0005 , A61K35/766 , A61K39/0011 , A61K39/12 , A61K2039/5254 , A61K2039/5256 , A61K2039/545 , A61K2039/55561 , A61K2039/572 , A61K2039/585 , C07K2319/00 , C07K2319/50 , C12N7/00 , C12N15/86 , C12N2710/10343 , C12N2710/16234 , C12N2710/20034 , C12N2740/15043 , C12N2760/20223 , C12N2760/20232 , C12N2760/20242 , C12N2760/20243 , A61K2300/00
摘要： There is described a kit for use in inducing an immune response in a mammal, the kit includes: a first virus that expresses MAGEA3, Human Papilloma Virus E6/E7 fusion protein, human Six-Transmembrane Epithelial Antigen of the Prostate protein, or Cancer Testis Antigen 1, or a variant thereof as an antigenic protein and that is formulated to generate an immunity to the protein or variant thereof in the mammal. The kit also includes a Maraba MG1 virus encoding the same antigen, or a variant of the same antigen. The Maraba MG1 virus is formulated to induce the immune response in the mammal. The first virus is immunologically distinct from the Maraba MG1 virus.
摘要翻译：描述了用于在哺乳动物中诱导免疫应答的试剂盒，该试剂盒包括：表达MAGEA3的第一种病毒，人乳头状瘤病毒E6 / E7融合蛋白，前列腺蛋白的人六跨膜上皮抗原或癌睾丸抗原1或其变体作为抗原性蛋白质，并且被配制成在哺乳动物中产生对蛋白质或其变体的免疫力。该试剂盒还包括编码相同抗原的Maraba MG1病毒，或相同抗原的变体。配制Maraba MG1病毒以诱导哺乳动物的免疫应答。第一种病毒与Maraba MG1病毒具有免疫学上的区别。

6. 发明申请

US20210052712A1 HETEROLOGOUS COMBINATION PRIME:BOOST THERAPY AND METHODS OF TREATMENT 有权
公开(公告)号：US20210052712A1
公开(公告)日：2021-02-25
申请号：US17045753
申请日：2019-04-09
申请人： CHILDREN'S HOSPITAL OF EASTERN ONTARIO RESEARCH INSTITUTE INC.
发明人： David F. STOJDL
IPC分类号： A61K39/00 , C07K14/005 , C07K14/47 , A61K39/12 , A61K35/17 , A61K9/00 , A61P35/00 , C12N7/00 , A61K39/205
摘要： The present disclosure provides a Farmington virus formulated to induce an immune response in a mammal against a tumour associated antigen. The Farmington virus may express an antigenic protein that includes an epitope from the tumour associated antigen. The Farmington virus may be formulated in a composition where the virus is separate from an antigenic protein that includes an epitope from the tumour associated antigen. The present disclosure also provides a prime:boost therapy for use in inducing an immune response in a mammal. The boost includes a Farmington virus, or a composition that includes a Farmington virus.

7. 发明申请

US20150275185A1 ONCOLYTIC RHABDOVIRUS 有权
公开(公告)号：US20150275185A1
公开(公告)日：2015-10-01
申请号：US14696028
申请日：2015-04-24
申请人： OTTAWA HOSPITAL RESEARCH INSTITUTE , CHILDREN'S HOSPITAL OF EASTERN ONTARIO RESEARCH INSTITUTE INC.
发明人： John C. BELL , David F. STOJDL
IPC分类号： C12N7/00 , A61K45/06 , A61K35/768 , A61K35/766
CPC分类号： C12N7/00 , A61K35/766 , A61K35/768 , A61K45/06 , C12N2760/20021 , C12N2760/20032 , C12N2760/20062 , C12N2760/20071 , A61K2300/00
摘要： Embodiments of the invention include compositions and methods related to Maraba virus and their use as anti-cancer therapeutics. Such rhabdoviruses possess tumor cell killing properties in vitro and in vivo.
摘要翻译：本发明的实施方案包括与Maraba病毒相关的组合物和方法及其作为抗癌治疗剂的用途。这种弹状病毒体外和体内具有肿瘤细胞杀伤性质。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式